An Osaka University-led research team has recently published findings that provide a ray of hope for the millions of Parkinson’s disease (PD) sufferers worldwide. Although more common in those aged over sixty, PD can strike at any age, with an estimated prevalence of 41 per 100,000 people in their forties. And while not fatal in and of itself, the progressive neurodegeneration that is characteristic of PD can often cause secondary effects that lead to death.
The exact cause of PD is still a mystery, but researchers believe that both genetics and the environment are likely to play a part. Importantly though, all PD patients show a loss of dopaminergic neurons in the brain and increased levels of a protein called ?-synuclein, which accumulates in Lewy bodies. Lewy bodies are a pathological feature of both familial and sporadic forms of the disease, as well as some types of dementia.
In the study published this month in Scientific Reports, the team led by researchers from Osaka University’s Graduate School of Medicine focused on ?-synuclein as a target for a novel PD treatment.
“Although there are drugs that treat the symptoms associated with PD, there is no fundamental treatment to control the onset and progression of the disease,” explains lead author Takuya Uehara. “Therefore, we looked at ways to prevent the expression of ?-synuclein and effectively eliminate the physiological cause of PD.”
To do this, the researchers designed short fragments of DNA that are mirror images of sections of the ?-synuclein gene product. The constructs were stabilized by the addition of amido-bridging. The resulting fragments, called amido-bridged nucleic acid-modified antisense oligonucleotides (ASOs), bind to their matching mRNA sequence, preventing it from being translated into protein. After screening 50 different ASOs, the researchers settled on a 15-nucleotide sequence that decreased ?-synuclein mRNA levels by 81%.
“When we tested the ASO in a mouse model of PD, we found that it was delivered to the brain without the need for chemical carriers,” says co-lead author Chi-Jing Choong. “Further testing showed that the ASO effectively decreased ?-synuclein production in the mice and significantly reduced the severity of disease symptoms within 27 days of administration.”
Explains senior author of the study Hideki Mochizuki, “Our results showed that gene therapy using ?-synuclein-targeting ASOs is a promising strategy for the control and prevention of PD. We expect that in the future, this method will be used to not only successfully treat PD, but also dementia caused by ?-synuclein accumulation.”
Learn more: Stopping Parkinson’s disease before it starts
The Latest on: Parkinson’s disease
[google_news title=”” keyword=”Parkinson’s disease” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Parkinson’s disease
- GB Sciences’ First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson’s Disease Has Been Issued in Chinaon March 20, 2023 at 4:06 am
According to Statista, China has the second largest pharmaceutical market in the world and plant-based medicines are very well accepted, which makes China a potential target market for Gb Sciences.
- What role does dysbiosis play in Parkinson's disease?on March 19, 2023 at 7:48 pm
The current study, published in the journal Revue Neurologique, is based on the hypothesis that dysbiosis, or unhealthy variations in the gut and oral microbiota, is a key component of PD pathogenesis ...
- Physical activity can help patients with Parkinson's disease improve their quality of life: Researchon March 19, 2023 at 8:18 am
Physical activity can improve both the quality of life and the severity of movement-related symptoms in Parkinson's disease patients. According to the preliminary Cochrane review of available research ...
- Parkinson's Research Newson March 18, 2023 at 5:01 pm
Jan. 10, 2023 — New research says the gut microbiome is involved in multiple pathways in the pathogenesis of Parkinson's disease. The findings show a wide imbalance in microbiome composition in ...
- Dry cleaning chemical linked to risk of Parkinson’s disease, study sayson March 16, 2023 at 2:31 pm
Researchers in a new study say the chemical pollutes air and can enter homes, schools, and workplaces undetected, and exposure to it could increase your risk of Parkinson's.
- Parkinson's: Could a common cleaning chemical cause the disease?on March 16, 2023 at 12:43 pm
A study found a link between Parkinson's disease and trichloroethylene (TCE), a chemical commonly used in dry cleaning, metal degreasing, and cleaning wipes.
- Parkinson’s Disease May be Caused by Common Dry-Cleaning Chemicalon March 16, 2023 at 6:30 am
New research suggests a chemical commonly used in dry-cleaning, degreasing, and even the decaffeination of coffee may be responsible for the steep increase in Parkinson’s disease cases.
- Parkinson's Disease Treatment: How Focused Ultrasounds May Help Reduce Symptomson March 15, 2023 at 5:00 pm
Share on Pinterest Experts say regular exercise and physical therapy can help with Parkinson’s disease symptoms. FG Trade/Getty Images Researchers say a targeted ultrasound treatment has shown ...
- How Michael J. Fox Stays Positive While Living With Parkinson's Disease: 'Pity Is a Benign Form of Abuse'on March 15, 2023 at 1:15 pm
Michael J. Fox does not have time to feel sorry for himself. During a screening for his documentary, Still: A Michael J. Fox Movie, at the South by Southwest (SXSW) Film Festival earlier this week, ...
- Michael J. Fox says Parkinson’s disease ‘sucks’ but he has a ‘great life’ and ‘no regrets’on March 15, 2023 at 5:32 am
The actor spoke out during a Q&A event at a special screening of his new documentary Still: A Michael J. Fox Movie at the SXSW Film Festival in Austin, Texas ...
via Bing News